SCHEMBL4473544

SCHEMBL4473544

CCOC(=O)/C=C/c1c(C#N)c2c(C)cc(C)nc2n1C(c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 6/20 0.36
KDM4E B2RXH2 6/20 0.36
HSD17B10 Q99714 2/20 0.36
HPGD P15428 1/20 0.36
MEN1 O00255 2/20 0.35
LMNA P02545 2/20 0.35
KMT2A Q03164 2/20 0.35
EPAS1 Q99814 1/20 0.35
RAB9A P51151 2/20 0.35
HTT P42858 2/20 0.34
IDO1 P14902 1/20 0.34
TDO2 P48775 1/20 0.34
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4475763 0.86 SMN1; SMN2 (0.39) CYP1A2CYP3A4CYP2C19ALDH1A1KDM4E
SCHEMBL4491294 0.84 POLB (0.38) CYP1A2CYP3A4CYP2C19ALDH1A1HPGD
SCHEMBL4491288 0.84 POLB (0.38) CYP1A2CYP3A4CYP2C19ALDH1A1HPGD
SCHEMBL4466725 0.82 SMN1; SMN2 (0.35) CYP1A2CYP3A4CYP2C19LMNARAB9A
SCHEMBL4466718 0.82 SMN1; SMN2 (0.35) CYP1A2CYP3A4CYP2C19LMNARAB9A
SCHEMBL4470782 0.80 SMN1; SMN2 (0.43) CYP1A2CYP2C19ALDH1A1KDM4EHPGD
SCHEMBL4467111 0.79 CYP1A2 (0.40) CYP1A2CYP3A4CYP2C19ALDH1A1KDM4E
SCHEMBL4481077 0.76 MAPK1 (0.33) KMT2ARAB9ATP53
SCHEMBL4481084 0.76 MAPK1 (0.33) KMT2ARAB9ATP53
SCHEMBL4494192 0.74 BACE1 (0.33) ALDH1A1MEN1LMNAKMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582651-B2 Pyrrolopyridine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-01 US disclosed
US-20060167038-A1 Pyrrolopyridine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-27 US disclosed
EP-1535922-A1 PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167038-A1 Pyrrolopyridine derivative and use thereof OPRD1, TRPV1, OPRM1 CYP1A2 936/4885CYP3A4 973/4885CYP2C19 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.